دورية أكاديمية
Improved glycemic control with weight loss and a low risk of hypoglycemia with insulin detemir: Insights from the Italian cohort of the PREDICTIVE study after 6-month observation in type 2 diabetic subjects
| العنوان: | Improved glycemic control with weight loss and a low risk of hypoglycemia with insulin detemir: Insights from the Italian cohort of the PREDICTIVE study after 6-month observation in type 2 diabetic subjects |
|---|---|
| المؤلفون: | Perriello, Gabriele, Caputo, Salvatore, De Pergola, Giovanni, Di Carlo, Alberto, Grassi, Giorgio, Lapolla, Annunziata, Pata, Pietro, Solerte, Sebastiano Bruno, Zaccardi, Francesco |
| المساهمون: | Perriello, Gabriele, Caputo, Salvatore, De Pergola, Giovanni, Di Carlo, Alberto, Grassi, Giorgio, Lapolla, Annunziata, Pata, Pietro, Solerte, Sebastiano Bruno, Zaccardi, Francesco |
| سنة النشر: | 2011 |
| المجموعة: | Università degli Studi di Bari Aldo Moro: CINECA IRIS |
| مصطلحات موضوعية: | insulin detemir, observational study of insulin detemir, predictive study, safety and efficacy of insulin detemir, Adult, Aged, Blood Glucose Self-Monitoring, Body Weight, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin A, Human, Hypoglycemia, Hypoglycemic Agent, Insulin, Long-Acting, Italy, Male, Middle Aged, Young Adult, Pharmacology, Pharmacology (medical) |
| الوصف: | Objective: PREDICTIVE (Predictable Results and Experience in Diabetes through Intensification and Control to Target: an International Variability Evaluation) is a large, multinational, open-label, prospective, observational study addressed to assess the efficacy and safety of insulin detemir in clinical practice. This paper reports 26 weeks of follow-up data, from 1298 type 2 diabetes patients from Italy. Research design and methods: In this observational study, the primary end point was the incidence of serious adverse drug reactions (SADRs), including major hypoglycemia. Secondary end points were: hemoglobin A1c (HbA1c), mean self-monitored fasting glucose, within-patient fasting glucose variability and body weight change. Results: Insulin detemir significantly improved glycemic control, with a decrease in mean HbA1c, fasting glucose and within-patient fasting glucose variability. Interestingly, the improvements in glycemic control occurred in association with a small, but significant reduction in weight. The safety results of this study showed that 26 weeks of treatment with insulin detemir was associated with a very low rate of SADRs (only 14 events), which mainly consisted of hypoglycemia (78%, of which 42% were major hypoglycemia). Conclusions: Insulin detemir improves glycemic control, with low risk of hypoglycemia, no weight gain and an excellent safety profile; these data support the overall findings of PREDICTIVE. © 2011 Informa UK, Ltd. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/wos/WOS:000295799600004; volume:12; issue:16; firstpage:2449; lastpage:2455; numberofpages:7; journal:EXPERT OPINION ON PHARMACOTHERAPY; http://hdl.handle.net/11586/215563Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-80054068546 |
| DOI: | 10.1517/14656566.2011.626766 |
| الإتاحة: | https://doi.org/10.1517/14656566.2011.626766Test http://hdl.handle.net/11586/215563Test |
| رقم الانضمام: | edsbas.CCD91C |
| قاعدة البيانات: | BASE |
| DOI: | 10.1517/14656566.2011.626766 |
|---|